Report
Gaetan Calabro ...
  • Mohamed Kaabouni
  • Nicolas Montel
  • Yann de Peyrelongue

PORTZAMPARC MIDCAP MIDDAY - 01-02-2022

ECOSLOPS: Record production in Sines - Strong Buy (1), TP: €15.0
ORPEA: Many questions remain - Hold (3) vs Strong Buy (1), TP: €50.0
OSE IMMUNO: €5m milestone on FR104 - Strong Buy (1), TP: €16.1
SOLUTIONS 30: Small acquisition in Poland – Suspended
Underlyings
Ecoslops SA

Ecoslops SA. Ecoslops SA is a France-based company principally engaged in the converting pertroleum residues from shipping (slops and sludge) in new marine fuels recycled. The Company offers seaports, residues collectors, ship-owners and bunker suppliers with a technology to recycle oily waste of ships. Ecoslops SA is active in promoting the development of the P2R unit by its incorporation in a more global plant: Oil Waste Processing Plant (OW2P). The OW2P technology combines a refining petroleum process (P2R) with appropriate clean water. The Company recycles the waste in order to be used in electricity production and steam production among others. The Company's fuel production is located in the port of Sines, Portugal.

Orpea SA

ORPEA is a dependency, physical and psychiatric care group based in France. Co. operates long-term and short-term care facilities, including medical care facilities, medical and social care facilities and residential facilities for the elderly. Co. provides short, medium and long-term global physical and mental dependency care. Co. also operates residential facilities for disabled people of any age, hotels, and hotel-related, as well as leisure accommodation facilities. Co. operates in France and abroad (Belgium, Italy, Spain and Switzerland) in three business segments: Long-term care facilities (nursing homes); Post-acute and Rehabilitation care facilities; and Psychiatric care facilities.

OSE Immunotherapeutics SA

Ose Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company principally engaged in the clinical stage biotechnological sector. The Company develops immunotherapy products against invasive or metastatic late-stage cancers. The Company offers a technology, called Memopi, which helps the immune system to eliminate malignant cells; it re-educates the body's immunological memory so that the immune system (and particularly T cytotoxic cells) attacks tumor cells by increasing the patient's specific cytotoxic T response against their cancer. The Company's main product, Texopi, is a patented combination of ten epitopes, selected and optimized from five tumor associated antigens.

Solutions 30 SE

Solutions 30 SE is a France-based company that specializes in information technology (IT) repair services for individual and business clients. Its activity is divided into five key fields, such as IT-Telecom, Energy, Audiovisual, Piont of services and Security. Solutions 30 SE has a network of locally based teams throughout France that provide on-site IT assistance either at home or in the workplace. The Company is also present in Italy. Solutions 30 SE operates through Telima Mediterranee, Telima Ile de France, Mulot Assistance, Telima Reims Family, Telima Mediterranee Family, Mixnet, B&F GmbH in Germany, Connecting Cable GmbH and Vodafone Kabel Deutschland Field Services Gmbh, among others.

Provider
Portzamparc Sponsored
Portzamparc Sponsored

​Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.

Analysts
Gaetan Calabro

Mohamed Kaabouni

Nicolas Montel

Yann de Peyrelongue

Other Reports on these Companies
Other Reports from Portzamparc Sponsored

ResearchPool Subscriptions

Get the most out of your insights

Get in touch